Chemotherapy-Induced Sclerosing Cholangitis Caused by Systemic Chemotherapy.


Journal

ACG case reports journal
ISSN: 2326-3253
Titre abrégé: ACG Case Rep J
Pays: United States
ID NLM: 101638398

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 07 01 2019
accepted: 20 06 2019
entrez: 18 10 2019
pubmed: 18 10 2019
medline: 18 10 2019
Statut: epublish

Résumé

A 61-year-old woman diagnosed with cervical cancer received systemic chemotherapy using paclitaxel and bevacizumab. Marked elevation of liver enzyme levels was observed. Ultrasonography and computed tomography showed wall thickening of the extrahepatic and intrahepatic bile ducts accompanied by stricture and dilatation. According to these, she was diagnosed as chemotherapy-induced sclerosing cholangitis (CISC), a form of secondary sclerosing cholangitis. Although CISC triggered by systemic chemotherapy is rare, CISC should be considered as a clinically important adverse event of chemotherapy because it causes rapid deterioration of liver function and necessitates interruption of chemotherapy.

Identifiants

pubmed: 31620533
doi: 10.14309/crj.0000000000000136
pii: ACGCR-19-0426
pmc: PMC6722363
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e00136

Informations de copyright

© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Références

Am J Gastroenterol. 2007 Jun;102(6):1221-9
pubmed: 17531010
Nihon Shokakibyo Gakkai Zasshi. 2005 Oct;102(10):1327-32
pubmed: 16262166
Nihon Shokakibyo Gakkai Zasshi. 2011 Feb;108(2):245-52
pubmed: 21307629
AJR Am J Roentgenol. 1986 Apr;146(4):717-21
pubmed: 2937274
J Clin Oncol. 1984 Jun;2(6):595-600
pubmed: 6233400
J Clin Gastroenterol. 2006 Apr;40(4):353-7
pubmed: 16633109
Am J Gastroenterol. 2005 Jun;100(6):1330-3
pubmed: 15929765
Nihon Shokakibyo Gakkai Zasshi. 2015 May;112(5):888-95
pubmed: 25947025
Sci Rep. 2017 Aug 1;7(1):7026
pubmed: 28765628
Dig Liver Dis. 2009 Jan;41(1):72-7
pubmed: 18294938
Clin Radiol. 2006 Aug;61(8):670-8
pubmed: 16843750

Auteurs

Akira Kusakabe (A)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Kazuyoshi Ohkawa (K)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Nobuyasu Fukutake (N)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Mitsuru Sakakibara (M)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Toshihiro Imai (T)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Yutaro Abe (Y)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Ryoji Takada (R)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Kenji Ikezawa (K)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Takatoshi Nawa (T)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Reiko Ashida (R)

Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Toshihiro Kimura (T)

Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan.

Shigenori Nagata (S)

Department of Diagnostic Pathology, Osaka International Cancer Institute, Osaka, Japan.

Kazuhiro Katayama (K)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Classifications MeSH